Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer.
PURPOSE It has been recognized for almost a decade that concentrations of signaling androgens sufficient to activate the androgen receptor are present in castration-resistant prostate cancer tissue. The source of these androgens is highly controversial, with three competing models proposed. We, therefore, wished to determine the androgenic potential of human benign and malignant (hormone-naïve ...
متن کاملPrognostic indicators in hormone refractory prostate cancer.
Prognostic factors in hormone refractory prostate cancer currently are of limited use to clinicians. Although studies have identified several factors that predict for poor survival in patients, most are either retrospective, or nonrandomized. Therefore, large prospective, randomized trials are needed to validate the significance of these factors. In addition, these indicators are largely descri...
متن کاملthe role of intermittent chemotherapy in the survival of patients with hormone refractory prostate cancer
introduction: prostate cancer is one of the most common cancers among males and the second factor resulting to death due to cancer among them.(1) the median age of its diagnosis is 65 years. the initial treatment includes androgen ablation or orchiectomy.(2, 3) in case of patient’s hormone refractory, chemotherapy would be substituted. the objective of this study is the consideration of intermi...
متن کاملTherapeutic approach to hormone-refractory prostate cancer.
Over 60 years ago, Huggins and Hodges discovered androgen deprivation as an effective first-line therapy for metastatic prostate cancer. This leads to significant cancer control but in almost all men prostate cancer ultimately progresses to a hormone-refractory (HRPC) state resulting in significant morbidity and eventual death. In 2004, two landmark studies using docetaxel based chemotherapy de...
متن کاملSatraplatin in the treatment of hormone-refractory metastatic prostate cancer
Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administration, 2) potential lack of cross-resistance with other platinum agents, 3) clinical benefits seen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2014
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-13-3483